Evidence map›Paper›PMID 26682141›Full record

ReviewQuantitative imaging in medicine and surgery2015

Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

Yewei Liu, Ting Yin, Yuanbo Feng, Marlein Miranda Cona, Gang Huang, Jianjun Liu, Shaoli Song, Yansheng Jiang, Qian Xia, Johannes V Swinnen and 4 more

Open access · greenAbstract readReview
In one paragraph

Review in Quantitative imaging in medicine and surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Potential of Corncob Extract on the Expression of Ki-67 and Caspase3 in Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Exposure to brominated flame retardantsFrontiers in endocrinology · 2024
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. The CRISPR/Cas System in Human Cancer.Advances in experimental medicine and biology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yewei Liu1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Ting Yin1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Yuanbo Feng1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Marlein Miranda Cona1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Gang Huang1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Jianjun Liu1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Shaoli Song1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Yansheng Jiang1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Qian Xia1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Johannes V Swinnen1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Guy Bormans1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Uwe Himmelreich1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Raymond Oyen1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
Yicheng Ni1 Theragnostic Laboratory, MoSAIC, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium ; 2 Department of Nuclear Medicine, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China ; 3 Laboratory of Lipid Metabolism and Cancer, Department of Oncology, 4 Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, 5 Biomedical MRI, MoSAIC, Department of Imaging and Pathology, 6 Radiology, Department of Imaging and Pathology, Faculty of Medicine, KU Leuven, Leuven 3000, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compared with transplanted tumor models or genetically engineered cancer models, chemically induced primary malignancies in experimental animals can mimic the clinical cancer progress from the early stage on. Cancer caused by chemical carcinogens generally develops through three phases namely initiation, promotion and progression. Based on different mechanisms, chemical carcinogens can be divided into genotoxic and non-genotoxic ones, or complete and incomplete ones, usually with an organ-specific property. Chemical carcinogens can be classified upon their origins such as environmental pollutants, cooked meat derived carcinogens, N-nitroso compounds, food additives, antineoplastic agents, naturally occurring substances and synthetic carcinogens, etc. Carcinogen-induced models of primary cancers can be used to evaluate the diagnostic/therapeutic effects of candidate drugs, investigate the biological influential factors, explore preventive measures for carcinogenicity, and better understand molecular mechanisms involved in tumor initiation, promotion and progression. Among commonly adopted cancer models, chemically induced primary malignancies in mammals have several advantages including the easy procedures, fruitful tumor generation and high analogy to clinical human primary cancers. However, in addition to the time-consuming process, the major drawback of chemical carcinogenesis for translational research is the difficulty in noninvasive tumor burden assessment in small animals. Like human cancers, tumors occur unpredictably also among animals in terms of timing, location and the number of lesions. Thanks to the availability of magnetic resonance imaging (MRI) with various advantages such as ionizing-free scanning, superb soft tissue contrast, multi-parametric information, and utility of diverse contrast agents, now a workable solution to this bottleneck problem is to apply MRI for noninvasive detection, diagnosis and therapeutic monitoring on those otherwise uncontrollable animal models with primary cancers. Moreover, it is foreseeable that the combined use of chemically induced primary cancer models and molecular imaging techniques may help to develop new anticancer diagnostics and therapeutics.

Indexed as

carcinogencarcinogenesisChemically induced primary malignancymagnetic resonance imaging (MRI)noninvasive imaging

Identifiers

PMID26682141
PMCPMC4671963
OpenAlexW1770655883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.